Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer

Journal of the National Cancer Institute

Volumn 103, Issue 17, 2011, Pages 1338-1342

  Lee, Chee K ^b   Friedlander, Michael ^a   Brown, Chris ^b   Gebski, Val J ^b   Georgoulopoulos, Alexander ^c   Vergote, Ignace ^d   Pignata, Sandro ^b   Donadello, Nicoletta ^f   Schmalfeldt, Barbara ^b,g   Delva, Rémy ^b,h   Mirza, Mansoor Raza ^b,i   Sauthier, Philippe ^e,j   Pujade Lauraine, Eric ^b,k   Lord, Sarah J ^b   Simes, R John ^b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f University of Varese   (Italy)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h CENTRE PAUL PAPIN   (France)

ⁱ Rigshospitalet   (Denmark)

^j NOTRE DAME HOSPITAL   (Canada)

^k UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; DOXORUBICIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OVARY CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; OVARIAN NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052681753     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr282     Document Type: Article

References (24)

1. Hawkins RE, Roberts K, Wiltshaw E, Mundy J, Fryatt IJ, McCready VR. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol. 1989;96(12):1395-1399.
2. van der Burg ME, Lammes FB, van Putten WL, Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol. 1988;30(3):307-312.
3. Tuxen MK, Soletormos G, Dombernowsky P. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer. 2001;84(10):1301-1307.
4. Hogberg T, Kagedal B. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet Gynecol Scand. 1990;69(5):423-429.
5. Rustin G, Nelstrop A, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996;14(5):1545-1551.
6. Vergote I, Rustin GJS, Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. J Natl Cancer Inst. 2000;92(18):1534-1535.
7. Rustin GJ, Quinn M, Thigpen T, et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004;96(6):487-488.
8. Coleman RL, Gordon A, Barter J, Sun S, Rackoff W, Herzog TJ. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist. 2007;12(1):72-78.
9. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28(20):3323-3329.
10. Anderson J, Cain K, Gelber R. Analysis of survival by tumor response. J Clin Oncol. 1983;1(11):710-719.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205-216.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
13. Cox DR. Regression models and life-tables. J Royal Stat Soc. 1972;34(2):187-220.
14. Kleinbaum D, Klein M. Survival Analysis. 2nd ed. New York, NY: Springer; 2005.
15. Alagkiozidis I, Facciabene A, Carpenito C, et al. Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. J Transl Med. 2009;7(1):104.
16. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 2008;14(3):263-273.
17. Pastorino F, Di Paolo D, Piccardi F, et al. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res. 2008;14(22):7320-7329.
18. Shaked Y, Emmenegger U, Francia G, et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res. 2005;65(16):7045-7051.
19. Markman M. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer. 2008;113(10):2832-2833.
20. Eisenhauer E, ten Bokkel Huinink W, Swenerton K, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12(12):2654-2666.
21. Rustin GJS, Bast RC, Kelloff GJ, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res. 2004;10(11):3919-3926.
22. Rustin GJS, Nelstrop AE, Bentzen SM, Bond SJ, McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol. 2000;18(8):1733-1739.
23. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicinversus topotecan. J Clin Oncol. 2001;19(14): 3312-3322.
24. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95(1):1-8.